Profiling cognitive impairment in treatment-resistant schizophrenia patients.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Psychiatry Research

• Publication date

  2016-01-30

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.psychres.2015.11.028PMID 26706131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

  2015cited by this paper
• Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review.

  2014cited by this paper
• Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

  2014cited by this paper
• The social and economic burden of treatment-resistant schizophrenia: a systematic literature review

  2014cited by this paper
• Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function

  2014cited by this paper
• Cognitive Rehabilitation of Schizophrenia Through Neurovr Training

  2013cited by this paper
• Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia.

  2013cited by this paper
• Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.

  2013cited by this paper
• Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment

  2013influential reference
• [The efficacy of cognitive neurorehabilitation with RehaCom program in schizophrenia patients].

  2013cited by this paper
• The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: a prospective three-year follow-up study.

  2013cited by this paper
• [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].

  2013cited by this paper
• Clozapine and visuospatial processing in treatment-resistant schizophrenia

  2013cited by this paper
• Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study

  2012cited by this paper
• Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

  2012cited by this paper
• A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia

  2012cited by this paper
• Nicotine dependence and illness severity in schizophrenia

  2012cited by this paper
• Symptomatic remission and neurocognitive functioning in patients with schizophrenia

  2011cited by this paper
• Antipsychotics in the treatment of schizophrenia: an overview.

  2011cited by this paper
• Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.

  2011cited by this paper
• Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

  2010cited by this paper
• International consensus study of antipsychotic dosing.

  2010cited by this paper
• Effect of second-generation antipsychotics on cognition: current issues and future challenges

  2010cited by this paper
• The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

  2009cited by this paper
• Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function.

  2009cited by this paper
• Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study

  2009cited by this paper
• Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia.

  2007cited by this paper
• Treatment-Resistant Schizophrenia.

  2007cited by this paper
• Treatment-resistant schizophrenia.

  2007cited by this paper
• Time-Dependent Cognitive Deficits Associated with First and Second Generation Antipsychotics: Cholinergic Dysregulation as a Potential Mechanism

  2007cited by this paper
• How should DSM-V criteria for schizophrenia include cognitive impairment?

  2007cited by this paper
• Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans.

  2005cited by this paper
• Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans.

  2005cited by this paper
• Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia.

  2004cited by this paper
• Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

  2004cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Practice guideline for the treatment of patients with schizophrenia, second edition.

  2004cited by this paper
• Acetylcholine: cognitive and brain functions.

  2003cited by this paper
• Effects of Scopolamine on Matching to Sample Paradigm and Related Tests in Human Subjects

  2003cited by this paper
• Acetylcholine modulation of neural systems involved in learning and memory.

  2003cited by this paper
• Kaplan and Sadock's Pocket Handbook of Psychiatric Drug Treatment

  2001cited by this paper
• Estimating significance level and power comparisons for testing multiple endpoints in clinical trials.

  2000cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system.

  1991cited by this paper
• Effects of anticholinergic medication on memory in schizophrenia.

  1990cited by this paper
• Methods for assessing positive and negative symptoms.

  1990cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper

• A novel supramolecular nanodrugs for improving the cognitive function of schizophrenia by protecting active lactone of arecoline.

  2025cites this paper
• Autonomic dysfunctions in psychotic disorders, interaction with antipsychotic intervention and treatment resistance: a comprehensive systematic review and meta-analysis.

  2025cites this paper
• Are cognitive deficits more severe among people with treatment-resistant schizophrenia than treatment responders?

  2025cites this paper
• Advancing Understanding of Treatment Response in Schizophrenia With Psychosis Using a Novel Dynamic Reward Task.

  2025cites this paper
• Effects of dose on early treatment response to bifrontal electroconvulsive therapy in Schizophrenia: A retrospective study.

  2025cites this paper
• Severity of autism-related symptoms in treatment-resistant schizophrenia: associations with cognitive performance, psychosocial functioning, and neurological soft signs - Clinical evidence and ROC analysis.

  2025cites this paper
• Investigation of cognitive functions in patients with rosacea: a case–control study

  2025cites this paper
• Network analysis of clinical features in patients with treatment-resistant schizophrenia

  2025cites this paper
• Cognitive function at first episode in patients subsequently developing treatment-resistant schizophrenia.

  2025cites this paper
• Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.

  2024cites this paper
• Formal Thought Disorders and Neurocognition in Treatment-Resistant Schizophrenia: Trouble du cours de la pensée et neurocognition dans la schizophrénie réfractaire

  2024cites this paper
• Association between treatment resistance and cognitive function in schizophrenia

  2024cites this paper
• Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.

  2024cites this paper
• The Ethiopian Cognitive Assessment battery in Schizophrenia (ECAS): a validation study

  2024cites this paper
• Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia

  2024cites this paper
• Patterns of Impaired Neurocognitive Performance on the Global Neuropsychological Assessment, and Their Brain Structural Correlates in Recent-onset and Chronic Schizophrenia

  2023cites this paper
• Development and Evaluation of a Cognitive Battery for People With Schizophrenia in Ethiopia.

  2023cites this paper
• Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy

  2023cites this paper
• Deep Learning-based Brain Age Prediction in Patients With Schizophrenia Spectrum Disorders.

  2023cites this paper
• Environmental exposure to organophosphate pesticides and effects on cognitive functions in elementary school children in a Middle Eastern area

  2023cites this paper
• Introducing an interview-based cognitive assessment tool for people with Schizophrenia in Ethiopia.

  2023cites this paper
• Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia.

  2023cites this paper
• Functional reconfiguration of cerebellum-cerebral neural loop in schizophrenia following electroconvulsive therapy.

  2022cites this paper
• Stage-Specific Brain Aging in First-Episode Schizophrenia and Treatment-Resistant Schizophrenia

  2022cites this paper
• Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

  2022cites this paper
• Association of cortical thickness and cognition with schizophrenia treatment resistance

  2022cites this paper
• Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.

  2022cites this paper
• LIMITING AND OPTIMISABLE CONDITIONS IN rTMS OF DEPRESSION AND OTHER MENTAL DISEASES INFLUENCE OF TMS, CLINICAL AND DEMOGRAPHIC PARAMETERS ON THE EFFICACY OF rTMS IN DEPRESSION BRAIN PERFUSION PATTERNS AS CLINICAL (NON) PREDICTOR TO aiTBS TREATMENT IN MEDICATION-RESISTANT DEPRESSION

  2022cites this paper
• Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature

  2022cites this paper
• Subjective cognitive functioning, depressive symptoms, and objective cognitive functioning in people with treatment-resistant psychosis

  2022cites this paper
• Altered Neuroanatomical Signatures of Patients With Treatment-Resistant Schizophrenia Compared to Patients With Early-Stage Schizophrenia and Healthy Controls

  2022influential citation
• Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

  2022cites this paper
• Patterns of impaired neurocognitive performance on Global Neuropsychological Assessment (GNA), and their brain structural correlates in recent-onset and chronic schizophrenia: A pilot study

  2022cites this paper
• Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

  2022cites this paper
• Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?

  2021cites this paper
• In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy

  2021cites this paper
• Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia

  2021cites this paper
• Oxytocin system dysfunction in patients with treatment-resistant schizophrenia: Alterations of blood oxytocin levels and effect of a genetic variant of OXTR.

  2021cites this paper
• A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance

  2021cites this paper
• Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia

  2021cites this paper
• Interacting Roles of COMT and GAD1 Genes in Patients with Treatment-Resistant Schizophrenia: a Genetic Association Study of Schizophrenia Patients and Healthy Controls

  2021cites this paper
• Shared Decision-Making and Role Preference Among Patients With Schizophrenia in Malaysia: A Cross-Sectional Study

  2021influential citation
• From Memories of Past Experiences to Present Motivation? A Meta-analysis on the Association Between Episodic Memory and Negative Symptoms in People With Psychosis.

  2021cites this paper
• Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis

  2021cites this paper
• Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study

  2021cites this paper
• Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients.

  2021cites this paper
• Evaluation of a Collaborative Care Program for Patients With Treatment-Resistant Schizophrenia: Protocol for a Multiple Case Study

  2021cites this paper
• The Role of Dopaminergic Genes in Probabilistic Reinforcement Learning in Schizophrenia Spectrum Disorders

  2021cites this paper
• S0033291721004128jrv 1..13

  2021cites this paper
• Evaluation of a collaborative care program for patients with treatment-resistant schizophrenia: Protocol for a multiple case-study. (Preprint)

  2021cites this paper
• Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

  2020influential citation
• The integrated model of glutamate and dopamine hypothesis for schizophrenia: Prediction and personalized medicine for prevent potential treatment-resistant patients.

  2020cites this paper
• Cognitive performance in early, treatment-resistant psychosis patients: Could cognitive control play a role in persistent symptoms?

  2020cites this paper
• Sex differences in association between clinical correlates and cognitive impairment in patients with chronic schizophrenia.

  2020cites this paper
• Autistic traits and cognitive profiles of treatment-resistant schizophrenia☆

  2020cites this paper
• Pathway-Phenotypes of Non-responders and Partial Responders to Treatment With Antipsychotics in Schizophrenia: A Machine Learning Study

  2020cites this paper
• Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia

  2020cites this paper
• Neurocognition and Treatment Outcomes in Schizophrenia

  2020cites this paper
• Thérapies innovantes et approches relationnelles dans la prise en charge des hallucinations auditives persistantes de la schizophrénie résistante et ultra-résistante : revue de la littérature

  2020cites this paper
• Treatment-Resistant Schizophrenia: Terminology and Clinical Features

  2020cites this paper
• Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?

  2019cites this paper
• Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study

  2019influential citation
• NEUROPEPTIDES AND OLIGOPEPTIDASES IN SCHIZOPHRENIA.

  2019cites this paper
• Preliminary examination of the validity of the NIH toolbox cognition battery in treatment-resistant psychosis

  2019cites this paper
• Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study

  2019cites this paper
• The impact of inflammation on neurocognition and risk for psychosis: a critical review

  2019cites this paper
• Integrated Psychological Therapy and Treatment-Resistant Schizophrenia: Initial Findings

  2019cites this paper
• White Matter in Schizophrenia Treatment Resistance.

  2019cites this paper
• Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?

  2019cites this paper
• Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study

  2019cites this paper
• Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia.

  2019cites this paper
• Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

  2019cites this paper
• Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks

  2018cites this paper
• Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome

  2018cites this paper
• A systems neuroscience perspective on treatment resistant schizophrenia : the role of cognitive control, reinforcement learning, and myelination

  2018cites this paper
• Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables

  2018influential citation
• Assessment of the Association Between Cigarette Smoking and Cognitive Performance in Patients With Schizophrenia-Spectrum Disorders: A Case-Control Study

  2018cites this paper
• Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.

  2018cites this paper
• Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study

  2018influential citation
• Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses.

  2018cites this paper
• Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia

  2018cites this paper
• When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity

  2017cites this paper
• Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.

  2017cites this paper
• Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study

  2016cites this paper
• Treatment resistant schizophrenia: Course of brain structure and function.

  2016cites this paper
• What do we know about treatment-resistant schizophrenia?

  2016cites this paper
• What do we know about treatment-resistant schizophrenia? – A systematic review

  2016cites this paper
• Neurocognition, Cognitive Remediation and Functional Outcome in Schizophrenia Spectrum Disorders

  2016cites this paper
• BRAIN PERFUSION ALTERATIONS INDUCED BY STANDALONE AND COMBINED TRANSCRANIAL STIMULATION OVER THE PREFRONTAL CORTEX: A RANDOMIZED, PLACEBO-CONTROLLED STUDY, USING 99mTc SPECT

  year unknowncites this paper